

Applicant: Cy A. Stein
Serial No.: Not Yet Known
(Continuation of U.S. Serial No. 09/109,614, filed July 2, 1998)
Filed: Herewith
Page: 2

the underlined materials as follows. Attached is a marked up copy and a clean copy of these claims.

Sub 3
B7
9. (Amended) [The] A composition of matter comprising an antisense oligonucleotide [of claim 3] comprising consecutive nucleotides, the nucleotide sequence of which is set forth in one of SEQ ID NOS: 1-13, wherein one or more [of the oligonucleotide's sugars] sugar of the oligonucleotide contain an -OMe group at [their] its 2' position.

Sub 8
B7
26. (Amended) A method of promoting the regression of vascular lesions, comprising introducing into a vascular cell an amount of [the] a composition of matter comprising an antisense oligonucleotide [of claim 3] comprising consecutive nucleotides, the nucleotide sequence of which is set forth in one of SEQ ID NOS: 1-13, effective to reduce the levels of bcl-xL protein produced, thereby promoting the regression of vascular lesions, wherein one or more sugar of the oligonucleotide contain an -OMe group at its 2' position.

Sub 3
B7
28. (Amended) The method of claim 26, wherein the introducing comprises using porphyrin [or lipofectin] as a delivery agent.

Please add new claim 36 as follows:

Sub 3
B7
Sub 3
36. (New) A composition of matter comprising an antisense oligonucleotide comprising consecutive nucleotides, the nucleotide sequence of which is set forth in one of SEQ I NOS: 1-13, wherein one or more sugar of the oligonucleotide is modified at its 2' position.